Amgen launches second trial for Alzheimer’s product
Amgen and Novartis launched a second trial for a product intended to delay or prevent Alzheimer’s disease, in partnership with the Banner Alzheimer’s Institute. The biotech giant based in Thousand Oaks had previously collaborated on the first study in the Alzhiemer’s Prevention Initiative Generation program, which enrolled participants who had two copies of the apolipoprotein Read More →
Amgen’s new drug for migraines shows promise
Thousand Oaks-based Amgen said a drug being developed in collaboration with Novartis showed promising results in providing relief for patients suffering from chronic migraines. The Phase 2 clinical trial met benchmarks for migraine reduction at two levels of dosage and with limited side effects. “Migraine is the sixth-leading cause of disability worldwide. Three to seven Read More →
Acelot’s software finds new drug combinations
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
